GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

The US Food and Drugs Administration (FDA) is expected to approve the JenaValve Trilogy System, a transcatheter aortic valve ...

Minimally invasive medtech can include surgical robots, miniaturized implants and therapeutic catheters — but it depends who ...

TAVIPILOT Soft is said to be a ‘world-first’ provision for real-time surgical guidance during TAVI and TAVR procedures.

Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker, citing concerns over its prospects in the market for Transcatheter ...

Self-Expanding TAVR May Have an Advantage A head-to-head trial of two widely used TAVR devices in patients with small aortic annuli, mostly women, showed differences in performance at 1 year in ...

A virtual start-up partnered with Nordson MEDICAL for complete design, development, and manufacturing of a catheter-based ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

“The positive results of the ALIGN-AR study provide a strong base and justification for moving forward with this registry studying whether TAVR with a dedicated device may be a solution for ...